Ultragenyx Pharmaceutical (RARE) FCF Margin (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of FCF Margin data on file, last reported at 145.59% in Q1 2026.

• FCF Margin for Q1 2026 came in at 145.59%, down 2544.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 74.96% (down 786.0% YoY), and the FY2025 annual result was 69.99%, up 519.0% from the prior year.
• FCF Margin fell to 145.59% in Q1 2026 per RARE's latest filing, from 48.13% in the prior quarter.
• Over five years, FCF Margin peaked at 40.45% in Q4 2023 and troughed at 178.02% in Q1 2022.
• A 5-year average of 99.13% and a median of 85.02% in 2022 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2023 and 2024: FCF Margin tumbled 5528 bps in 2023, then jumped 10526 bps in 2024.
• A 5-year view of FCF Margin shows it stood at 85.02% in 2022, then surged by 52 bps to 40.45% in 2023, then slipped by 19 bps to 48.27% in 2024, then advanced by 0 bps to 48.13% in 2025, then sank by 202 bps to 145.59% in 2026.
• Business Quant data shows RARE's FCF Margin at 145.59% in Q1 2026, 48.13% in Q4 2025, and 57.96% in Q3 2025.